文献速递前列腺癌

基于多参数磁共振的临床可用决策支持方案优化前列腺穿刺活检

A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-24

回顾性纳入229例疑似前列腺癌患者,评估多参数磁共振特征对穿刺活检效果的影响,并开发基于多参数磁共振评估的决策支持方案作为分诊工具,系统比较不同策略的成本效果。结果显示靶向穿刺在PI-RADS 5分及较大(≥1 cm)PI-RADS 3-4分病灶中可准确检出所有前列腺癌,仅对较小(<1 cm)PI-RADS 3-4分病灶加用系统穿刺可提高检出率并降低升级率。

要点

  • 靶向穿刺诊断前列腺癌和临床显著前列腺癌的检出率与联合穿刺相当,且优于系统穿刺。
  • 在PI-RADS 5分和较大(≥1 cm)PI-RADS 3-4分病灶中,靶向穿刺检出全部前列腺癌(72.5%),加用系统穿刺仅使1.4%临床显著前列腺癌升级。
  • 对较小(<1 cm)PI-RADS 3-4分病灶,联合穿刺检出率较高且升级率较低。

核心结论

  • 系统穿刺的额外获益主要局限于较小的PI-RADS 3-4分病灶。
  • 采用对PI-RADS 5分和较大(≥1 cm)PI-RADS 3-4分病灶仅行靶向穿刺的个体化策略,可在不降低检出率的情况下避免44.5%(102/229)的初次活检患者接受多余的系统穿刺。

研究设计与样本

  • 回顾性纳入229例疑似前列腺癌患者,在联合靶向穿刺/系统穿刺前接受多参数磁共振检查。
  • 评估磁共振特征(PI-RADS评分、病灶大小、带区起源和位置)对活检效果的影响。
  • 开发基于多参数磁共振评估的临床可用决策支持方案作为分诊测试,系统比较成本(降级、升级和穿刺针数)与效果(检出率)。

主要发现

  • 靶向穿刺诊断前列腺癌和临床显著前列腺癌的检出率与联合靶向穿刺/系统穿刺相当(前列腺癌:59%[135/229] vs 60.7%[139/229];临床显著前列腺癌:45.9%[105/229] vs 47.2%[108/229];P值均>0.05),且优于系统穿刺(前列腺癌:42.4%[97/229];临床显著前列腺癌:28.4%[65/229];P值均<0.001)。
  • 在个体化决策支持方案中,靶向穿刺准确检出PI-RADS 5分和较大(≥1 cm)PI-RADS 3-4分病灶中的所有前列腺癌(72.5%[74/102]),加用系统穿刺仅导致1.4%(1/74)的临床显著前列腺癌升级。
  • 对于较小(<1 cm)PI-RADS 3-4分病灶,联合靶向穿刺/系统穿刺较靶向穿刺检出率相对较高(51.2%[65/127] vs 48.0%[61/127]),升级率较低(30.6%[15/49] vs 36.7%[18/49])。

临床怎么用

  • 作者认为,对PI-RADS 5分和较大(≥1 cm)PI-RADS 3-4分病灶采用仅靶向穿刺的个体化策略,可在不降低检出率的情况下避免44.5%(102/229)的初次活检患者接受多余的系统穿刺。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined MRI/Ultrasound fusion targeted biopsy (TBx) and systematic biopsy (SBx) results in better prostate cancer (PCa) detection relative to either TBx or SBx alone, while at the cost of higher number of biopsy cores and greater detection of clinically insignificant PCa. We therefore developed and evaluated a simple decision support scheme for optimizing prostate biopsy based on multiparametric (mp) MRI assessment. METHODS: Total 229 patients with suspicion of PCa underwent mpMRI before combined TBx/SBx were retrospectively included. Impacts of MRI characteristics such as Prostate Imaging-Reporting and Data System (PI-RADS) score, lesion size, zonal origination, and location on biopsy performance were evaluated. A clinically available decision support scheme relying on mpMRI assessment was subsequently developed as a triage test to optimize prostate biopsy process. Cost (downgrade, upgrade, and biopsy core)-to-Effectiveness (detection rate) was systemically compared. RESULTS: TBx achieved comparable detection rate to combined TBx/SBx in diagnosis of PCa and clinically significant PCa (csPCa) (PCa, 59% [135/229] vs 60.7% [139/229]; csPCa, 45.9% [105/229] vs 47.2% [108/229]; p-values > 0.05) and outperformed SBx (PCa, 42.4% [97/229]; csPCa, 28.4% [65/229]; p-values < 0.001). Specially, in personalized decision support scheme, TBx accurately detected all PCa (72.5% [74/102]) in PI-RADS 5 and larger (≥1 cm) PI-RADS 3-4 observations, adding SBx to TBx only resulted in 1.4% (1/74) upgrading csPCa. For smaller (<1 cm) PI-RADS 3-4 lesions, combined TBx/SBx resulted in relatively higher detection rate (51.2% [65/127] vs 48.0% [61/127]) and lower upgrading rate (30.6% [15/49] vs 36.7% [18/49]) than TBx. CONCLUSIONS: The benefit of SBx added to TBx was largely restricted to smaller PI-RADS score 3-4 lesions. Using our personalized strategy of solo TBx for PI-RADS 5 and larger (≥1 cm) PI-RADS score 3-4 lesions would avoid excess SBx in 44.5% (102/229) of all biopsy-naïve patients without compromising detection rate.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Hou Y, Jiang KW, Zhang J, et al. A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI. Prostate Cancer Prostatic Dis. 2022. PMID: 35067674. doi:10.1038/s41391-021-00489-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。